UB Paderborn / Katalog / Suche / in CDI

Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD

Chest, 2017-02, Vol.151 (2), p.340-357

2017

Volltextzugriff (PDF)

Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology

European journal of pharmaceutical sciences, 2018-01, Vol.111, p.450-457

2018

Volltextzugriff (PDF)

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

Journal of clinical pharmacology, 2008-05, Vol.48 (5), p.592-598

2008

Volltextzugriff (PDF)

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD

Respiratory research, 2017-08, Vol.18 (1), p.157-157, Article 157

2017

Volltextzugriff (PDF)

Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology

Pulmonary pharmacology & therapeutics, 2018-04, Vol.49, p.67-74

2018

Volltextzugriff (PDF)

Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

ERJ open research, 2023-07, Vol.9 (3), p.695

2023

Volltextzugriff (PDF)

Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease

Respiratory investigation, 2021-01, Vol.59 (1), p.135-144

2021

Volltextzugriff (PDF)

Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies

The AAPS journal, 2008, Vol.10 (1), p.141-147

2008

Volltextzugriff (PDF)

Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma

Annals of allergy, asthma, & immunology, 2022-02, Vol.128 (2), p.169-177

2022

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-1 INHIBITION WITH BRENSOCATIB IN THE FREQUENT EXACERBATOR PHENOTYPE: A SUBGROUP ANALYSIS FROM THE WILLOW TRIAL

Chest, 2023-10, Vol.164 (4), p.A4961-A4962

2023

Volltextzugriff (PDF)

Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent

Pulmonary pharmacology & therapeutics, 2018-08, Vol.51, p.18-25

2018

Volltextzugriff (PDF)

A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment

The Journal of asthma, 2022-07, Vol.59 (7), p.1420-1432

2022

Volltextzugriff (PDF)

Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: The TYREE study

Annals of allergy, asthma, & immunology, 2022-02, Vol.128 (2), p.169-177

2022

Volltextzugriff (PDF)

Long term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease

Respiratory medicine, 2017-05, Vol.126, p.105-115

2017

Volltextzugriff (PDF)

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects

Pulmonary pharmacology & therapeutics, 2018-12, Vol.53, p.33-38

2018

Volltextzugriff (PDF)

Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults

Clinical pharmacology in drug development, 2019-02, Vol.8 (2), p.223-233

2019

Volltextzugriff (PDF)

Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials

Clinical drug investigation, 2021-06, Vol.41 (6), p.579-590

2021

Volltextzugriff (PDF)

Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease

Respiratory medicine, 2018-05, Vol.138, p.74-80

2018

Volltextzugriff (PDF)

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.2969-2984

2018

Volltextzugriff (PDF)

EPD15-4. Safety and Pharmacokinetics of Budesonide / glycopyrronium / formoterol fumarate Dihydrate Metered-Dose Inhaler (BGF-MDI) in Healthy Adult Subjects of Japanese Descent

日本呼吸器学会誌, 2019-03, Vol.8 (suppl), p.386-386

2019

Volltextzugriff (PDF)

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.945-953

2018

Volltextzugriff (PDF)

Beneficial Effect of GFF MDI: A LAMA/LABA FDC Delivered by MDI Using Novel Cosuspension Technology on Inspiratory Capacity in Patients With COPD

Chest, 2016-10, Vol.150 (4), p.839A-839A

2016

Volltextzugriff (PDF)

An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

Journal of aerosol medicine and pulmonary drug delivery, 2019-02, Vol.32 (1), p.40

2019

Volltextzugriff (PDF)

Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.43-56

2020

Volltextzugriff (PDF)

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.1187-1194

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD

Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD

Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology

Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease

Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies

Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma

EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-1 INHIBITION WITH BRENSOCATIB IN THE FREQUENT EXACERBATOR PHENOTYPE: A SUBGROUP ANALYSIS FROM THE WILLOW TRIAL

Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent

A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment

Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: The TYREE study

Long term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects

Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials

Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

EPD15-4. Safety and Pharmacokinetics of Budesonide / glycopyrronium / formoterol fumarate Dihydrate Metered-Dose Inhaler (BGF-MDI) in Healthy Adult Subjects of Japanese Descent

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD

Beneficial Effect of GFF MDI: A LAMA/LABA FDC Delivered by MDI Using Novel Cosuspension Technology on Inspiratory Capacity in Patients With COPD

An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD

Suchergebnisse filtern